XBIT PE Ratio & Valuation,Is XBIT Overvalued

XBIT Relative Valuation

XBIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XBIT is overvalued; if below, it's undervalued.

Historical Valuation

XBiotech Inc (XBIT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.15 is considered Fairly compared with the five-year average of 24.33. The fair price of XBiotech Inc (XBIT) is between 0.85 to 2.82 according to relative valuation methord.

Relative Value

Fair Zone

0.85-2.82

Current Price：2.40

Fair

0.00

EV/EBITDA

XBiotech Inc. (XBIT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.31

EV/EBIT

XBiotech Inc. (XBIT) has a current EV/EBIT of -0.31. The 5-year average EV/EBIT is 26.65. The thresholds are as follows: Strongly Undervalued below -84.33, Undervalued between -84.33 and -28.84, Fairly Valued between 82.14 and -28.84, Overvalued between 82.14 and 137.63, and Strongly Overvalued above 137.63. The current Forward EV/EBIT of -0.31 falls within the Historic Trend Line -Fairly Valued range.

0.15

XBiotech Inc. (XBIT) has a current PS of 0.15. The 5-year average PS is 3.84. The thresholds are as follows: Strongly Undervalued below -10.19, Undervalued between -10.19 and -3.17, Fairly Valued between 10.85 and -3.17, Overvalued between 10.85 and 17.87, and Strongly Overvalued above 17.87. The current Forward PS of 0.15 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

XBiotech Inc. (XBIT) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.30

P/FCF

XBiotech Inc. (XBIT) has a current P/FCF of 0.30. The 5-year average P/FCF is -2.14. The thresholds are as follows: Strongly Undervalued below -13.10, Undervalued between -13.10 and -7.62, Fairly Valued between 3.34 and -7.62, Overvalued between 3.34 and 8.83, and Strongly Overvalued above 8.83. The current Forward P/FCF of 0.30 falls within the Historic Trend Line -Fairly Valued range.

XBiotech Inc (XBIT) has a current Price-to-Book (P/B) ratio of 0.44. Compared to its 3-year average P/B ratio of 0.69 , the current P/B ratio is approximately -36.98% higher. Relative to its 5-year average P/B ratio of 0.86, the current P/B ratio is about -49.29% higher. XBiotech Inc (XBIT) has a Forward Free Cash Flow (FCF) yield of approximately -32.59%. Compared to its 3-year average FCF yield of -18.36%, the current FCF yield is approximately 77.54% lower. Relative to its 5-year average FCF yield of -8.71% , the current FCF yield is about 274.33% lower.

0.44

P/B

Median3y

0.69

Median5y

0.86

-32.59

FCF Yield

Median3y

-18.36

Median5y

-8.71

Competitors Valuation Multiple

The average P/S ratio for XBIT's competitors is 213.98, providing a benchmark for relative valuation. XBiotech Inc Corp (XBIT) exhibits a P/S ratio of 0.15, which is -99.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of XBIT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of XBIT in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XBiotech Inc (XBIT) currently overvalued or undervalued?

What is XBiotech Inc (XBIT) fair value?

XBIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of XBiotech Inc (XBIT) is between 0.85 to 2.82 according to relative valuation methord.

How does XBIT's valuation metrics compare to the industry average?

What is the current P/B ratio for XBiotech Inc (XBIT) as of Dec 15 2025?

As of Dec 15 2025, XBiotech Inc (XBIT) has a P/B ratio of 0.44. This indicates that the market values XBIT at 0.44 times its book value.

What is the current FCF Yield for XBiotech Inc (XBIT) as of Dec 15 2025?

As of Dec 15 2025, XBiotech Inc (XBIT) has a FCF Yield of -32.59%. This means that for every dollar of XBiotech Inc’s market capitalization, the company generates -32.59 cents in free cash flow.

What is the current Forward P/E ratio for XBiotech Inc (XBIT) as of Dec 15 2025?

As of Dec 15 2025, XBiotech Inc (XBIT) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of XBiotech Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for XBiotech Inc (XBIT) as of Dec 15 2025?

As of Dec 15 2025, XBiotech Inc (XBIT) has a Forward P/S ratio of 0.15. This means the market is valuing XBIT at $0.15 for every dollar of expected revenue over the next 12 months.

XBIT Valuation